Topline data were announced from two phase 3 trials evaluating ulixacaltamide in patients with essential tremor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback